Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2022 | Genomically aggressive or indolent smoldering myeloma and progression to multiple myeloma

Niccolò Bolli • 25 Sep 2022
IMS 2022
Multiple Myeloma Rare Diseases Smoldering Myeloma

Niccolò Bolli, MD, PhD, University of Milan, Milan, Italy, comments on features that are characterized as genomically aggressive or indolent in patients with smoldering myeloma, and discusses their impact on progression to multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Niccolò Bolli

The role of the bone marrow immune microenvironment on response to treatment in multiple myeloma 2:26
The role of the bone marrow immune microenvironment on response to treatment in multiple myeloma
Niccolò Bolli • 25 Aug 2022
Clinical and genomic diagnosis of smoldering myeloma & identifying patients at risk of progression 2:45
Clinical and genomic diagnosis of smoldering myeloma & identifying patients at risk of progression
Niccolò Bolli • 25 Aug 2022
Session highlights: clonal hematopoiesis in multiple myeloma 2:43
Session highlights: clonal hematopoiesis in multiple myeloma
Niccolò Bolli • 25 Aug 2022
The association between CHIP and MGUS 4:02
The association between CHIP and MGUS
Niccolò Bolli • 12 Dec 2021

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals